<DOC>
	<DOCNO>NCT02046122</DOCNO>
	<brief_summary>The primary hypothesis chemotherapy follow donor lymphocyte infusion ( DLI ) HLA-haploidentical donor safe procedure cause Graft versus Host Disease ( GVHD ) increase treatment-related mortality . The Investigator believe improve outcome elderly patient high-risk AML MDS compare chemotherapy alone , benefit even great donor-recipient pair share maternal-fetal microchimerism non-inherited maternal antigen ( NIMA ) mismatch . A large part trial include immune function assay well assessment efficacy , toxicity , GVHD . Because therapy may tolerable alternative allogeneic hematopoietic stem cell transplantation ( alloHSCT ) elderly patient , Investigator validate functional measurement ( e.g . Comprehensive Geriatric Assessment ( CGA ) ) biologic correlate ( cytokine genomic profile ) clinical outcome .</brief_summary>
	<brief_title>Adoptive Transfer Haplo-identical DLI AML MDS</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<criteria>1 . Subjects must diagnosis highrisk AML highrisk MDS confirm pathologic review bone marrow biopsy accord WHO guideline 2 . Patients define high risk AML thus eligible meet one follow criterion : 1 . Secondary AML ( underlie MDS therapy relate ) 2 . Presence complex cytogenetic abnormality ( 3 cytogenetic abnormality ) , monosomy , del 5q , del 7q , inv3 , ( 3 ; 3 ) , ( 6 ; 9 ) , ( 9 ; 22 ) , abn 11q23 ( exclude ( 9 ; 11 ) ) 3 . Fmslike tyrosine kinase 3 ( FLT3 ) internal tandem duplication ( ITD ) mutation positive 4 . Age ≥ 65 year give poor outcome even favorable cytogenetics 3 . Patients define high risk MDS thus eligible MD Anderson Comprehensive Cancer MDS Risk Score ≥9 4 . Subjects must Eastern Cooperative Oncology Group ( ECOG ) Performance status 0,1 , 2 ; ECOG 2 , must also Charlson comorbidity index ≤5 . 5 . Subjects must 55 year age old 6 . Subjects 35/6 HLAmatched related haploidentical donor evaluate deem able provide DLI . 7 . Patient able provide inform consent 8 . Subjects must multigated acquisition ( MUGA ) /or ECHO cardiac magnetic resonance imaging ( MRI ) . The required minimum standard include MUGA ECHO cardiac MR show ejection fraction ( EF ) 40 % . Those EF 4049 % must also cardiologist consult assist management . 9 . Pulmonary function test ( PFTs ) diffuse capacity lung carbon monoxide ( DLCO ) conditional subject discretion physician . The required minimum standard PFTs include DLCO 40 % . Those DLCO 4049 % must pulmonologist consult assist management . 10 . Subjects gender race eligible 1 . Pregnant lactating woman . 2 . Patients major medical psychiatric illness treat physician feel could seriously compromise tolerance protocol 3 . Patients know active central nervous system ( CNS ) disease 4 . Patients acute promyelocytic leukemia ( FAB M3 )</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>